シラミ治療の世界市場-2023年～2030年

概要

シラミ治療の世界市場は2022年に1億米ドルに達し、2023-2030年の予測期間中にCAGR 6.3％で成長し、2030年には2億米ドルに達すると予測されています。

シラミは通常、衣服、帽子、スカーフ、クシ、ブラシ、整髪料、ヘルメットなどをシラミと共有することで、子どもから子どもへと感染します。また、接触スポーツ中に感染することもあります。アタマジラミは、特に首の後ろや耳の後ろなど、頭皮に近い髪の根元に小さな白い卵を産み付けます。

治療後、感染者は拡大鏡と明るい光を使って、シラミの有無を他の人にチェックしてもらう必要があります。通常、治療が推奨されるのは、活動的な感染と診断された人（家族全員と密接な接触者を含む）です。予防的治療は、活発に感染している人と同じベッドを共有している人に勧められます。すべての感染者とその同衾者は同時に治療されるべきです。薬理学的治療と補助的治療を併用することもできますが、一般的にアタマジラミの蔓延をなくすために必要なものではありません。

さらに、世界のシラミ治療は、先進技術開発のための投資の増加、新興国市場の増加、研究開発の増加、Alliance Pharmaceuticals、Omega Pharma（Perrigo Company）、Prestige Brands Holdings Inc、Johnson &Johnson Private Limitedなどの重要な主要企業を有する治療オプションの進歩など、様々な要因によって牽引されています。

ダイナミクス

シラミ蔓延率の上昇

シラミ蔓延率の上昇は、予測期間中に市場を牽引する要因の1つです。アタマジラミ症（Pediculosis capitis）は一般的な健康問題であり、義務的な外部寄生虫であるヒトジラミ（Pediculus humanus capitis）によって引き起こされる感染症であり、ヒトの頭皮のみに感染します。

例えば、国立医学図書館のHealth Equityが発表した論文によると、ブラジルの貧しい農村地域と都市のスラムにおけるアタマジラミの有病率は、それぞれ28％から43％と推定されています。子どもたちが最も感染しやすく、多くの場合、学校内で集団感染しています。私たちは、資源の乏しい地域社会におけるアタマジラミの有病率を下げる方法として、科学的情報と地元の伝統的な治療法を用いて、アタマジラミにまつわる社会的スティグマに取り組むことを意図したプログラムを開始しました。

規制当局による製品承認の増加

シラミ治療製品には有効性・品質・ラベリングの確認のために規制当局の承認が必要です。そのため、規制当局による製品承認は、シラミ治療市場において重要な役割を果たしています。したがって、各国の規制当局による製品承認の増加は、世界のシラミ治療市場の成長を促進する可能性があります。例えば、2022年4月、アーバー・ファーマシューティカルズ・インク（アズリティ・ファーマシューティカルズ・インクの子会社）は、毛髪軸と頭皮からシラミと卵を駆除し、安全に除去するための天然成分を含む新規ヘアケア技術について、米国とカナダで特許を取得しました。

新製品上市の増加

新製品の導入は、合併症の少ない治療に役立つ改良された製剤と迅速な送達メカニズムを作成するため、新製品の技術革新は、予測期間中にこの市場を促進するために重要な役割を果たしています。例えば、2023年6月21日、インドを拠点とする毛髪・頭皮用トリートメントメーカーのChosen by Dermatology社は、植物成分を多く含む毛髪用美容液「Child's Play」を発売しました。この製品は、シラミやダニを治療する際に洗い流す製品として使用できます。

児童の人口増加：シラミ治療市場シェアの成長を支えるもう一つの要因

世界中で児童の数が増加していることから、予測期間中にシラミ治療ソリューションの需要が高まると予想されます。児童は成人と比較して、個人的な空間や衛生に対する保護意識が低いため、シラミに感染しやすいです。世界中で人口が急増しているため、児童の数の増加が予測期間中の市場成長を促進すると予想されます。また、シラミ感染の有病率の上昇は、衛生やシラミ感染に関する意識の欠如のため、農村部や都市部と比較して、遊牧民族の児童で著しく高いです。

シラミ治療に伴う副作用

シラミ治療の合併症は、予測期間中に市場の成長を妨げる抑制要因の1つです。例えば、かゆみ、腫れ、赤みなどの頭皮の炎症は、アタマジラミで起こり、ペルメトリンによる治療後に一時的に悪化することがあります。

また、人々の認識不足が世界のシラミ治療市場の成長を妨げると予想されます。例えば、アタマジラミの治療に関する家族の認識不足から、殺虫剤や灯油を含む伝統的な薬を直接使用することがしばしばありますが、これは非常に有害であり、最終的には治療を受けている人の死を招く可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • シラミ蔓延率の上昇
    • 規制当局による製品承認の増加
    • 製品上市の増加
    • 児童の人口増加：シラミ治療市場シェアの成長を支えるもう一つの要因
  • 抑制要因
    • シラミ治療に伴う副作用
  • 機会
    • 研究開発の増加
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 タイプ別

• 頭部毛ジラミ寄生症
• 体部毛ジラミ寄生症
• 陰部毛ジラミ寄生症

第8章 薬剤別

• 一般用医薬品（OTC）
• 処方薬

第9章 流通チャネル別

• 病院
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Alliance Pharmaceuticals
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Omega Pharma（Perrigo Company）
• Prestige Brands Holdings Inc.
• Johnson & Johnson Private Limited
• Fleming Medical Ltd
• RID Lice（Oystershell Consumer Health, Inc）
• Nisarg Pharma
• ParaPRO Pharmaceuticals
• ICB Pharma
• Marico

第13章 付録

Overview

Global Lice Treatment Market reached US$ 0.1 billion in 2022 and is expected to reach US$ 0.2 billion by 2030, growing with a CAGR of 6.3% during the forecast period 2023-2030.

Lice are typically transmitted from child to child through sharing clothing, hats, scarves, combs, brushes, hair trims, or helmets with nits. They can also be passed during contact sports. Head lice lay small white eggs at the base of hair near the scalp, particularly on the back of the neck and behind the ears.

After treatment, the infected person should be checked by another person for lice and nits using a magnifying glass and bright light. Treatment is usually recommended for persons diagnosed with an active infestation, including all household members and close contacts. Prophylactic treatment is advised for those sharing the same bed with actively-infested individuals. All infested persons and their bedmates should be treated simultaneously. Supplemental measures can be combined with pharmacologic treatment, but these are generally not required to eliminate a head lice infestation.

Furthermore, the global lice treatment is driven by various factors like, rising investment for the development of advanced technologies, an increase in the number of emerging markets, a rise in research and development, advancements in treatment options having significant key players like Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc, Johnson & Johnson Private Limited and among others.

Dynamics

Rise in the Prevalence of Lice Infestation

The rise in the prevalence of lice infestation is one of the factors to drive the market during the forecast period. Infestation with head lice (Pediculosis capitis) is a common health problem, it is an infectious condition caused by an obligatory ectoparasite, the human louse (Pediculus humanus capitis) and affects only the human scalp.

For instance, according to the article published by Health Equity in the National Library of Medicine, the prevalence of head lice in poor rural communities and urban slums is estimated to be between 28% and 43% in Brazil, respectively. Children are among the most affected, often in clusters within schools. We launched a program intending to tackle the social stigma associated with head lice using scientific information and a local traditional remedy as a way to lower the prevalence of head lice in a low-resource community.

Rise in Product Approvals by Regulatory Authorities

Product approvals by regulatory authorities play an important role in the lice treatment market as lice treatment products required regulatory approvals to check efficacy, quality and labelling. Hence the increasing product approvals by regulatory agencies of respective countries can drive the growth of the global lice treatment market. For instance, in April 2022, Arbor Pharmaceuticals Inc. (A subsidiary of Azurity Pharmaceuticals, Inc.), issued patents in the U.S. and Canada for its novel hair care technology containing all-natural ingredients to dislodge and safely remove lice and eggs from the hair shaft and scalp.

Increase in The Product Launches

Innovation of new products plays an important role to drive this market during the forecast period, as introducing new products creates improved formulations and fast delivery mechanisms which helps in the treatment have fewer complications. For instance, on June 21, 2023, Chosen by Dermatology- an India-based manufacturer of hair and scalp treatments, launched Child's Play, a hair serum with high plant content. The product can be used as a wash-off product when used to treat lice and nits.

Rise in the Population of Children Is Another Factor Supporting the Lice Treatment Market Share Growth

The rising number of children across the globe is expected to raise the demand for lice treatment solutions during the forecast period. Children are more prone to lice infestation as compared to adults, as they are less protective of their personal space and hygiene. There is a rapid rise in population across the globe; hence, the rising number of children is expected to propel market growth during the forecast period. The rising prevalence of lice infestation is also significantly high in children from nomad tribes, as compared to rural and urban areas due to lack of hygiene and awareness regarding lice infestation.

Side Effects Associated With Lice Treatment

Complications of lice treatments are one of the restraints that hamper the market from growth during the forecast period. Some of them are like Scalp irritation, including itching, swelling, or redness may occur with head lice and temporarily worsen after treatment with permethrin.

Also, A lack of awareness among people is expected to hamper the growth of the global lice treatment market. For instance, the lack of awareness of families about treating head lice often leads to the direct use of traditional medicines, including insecticides or kerosene, which can be very harmful and ultimately cause the death of the person being treated.

Segment Analysis

The global lice treatment market is segmented based on type, medication, distribution channel and region.

The Permethrin Segment From The Medication Segment Accounted for Approximately 41.7% of the Lice Treatment Share

The permethrin segment from the medication segment accounted for 41.7% and it is expected to be dominated during the forecast period. Permethrin treats scabies in adults and children two months of age and older. Over-the-counter permethrin is used to treat head lice (tiny insects that attach to the skin on the head) in adults and children two months of age and older. Permethrin is part of a group of medicines called scabies and Insecticides. It's effective in killing lice and mites.

Furthermore, according to NCBI in May 2022, permethrin is a common first-line treatment option for head lice infestations, which is available over the counter in many countries and a systematic review of trials that evaluated medications for the treatment of head lice suggested that permethrin was very much effective.

Also, the hospitals and clinics segment is expected to dominate during the forecast period. For instance, in August 2023 Hairline International Hair and Skin Clinic opened India's first-ever LICE Clinic to combat Head Lice Infestation. Head lice, a common concern among parents and children, can cause scalp itching and potential bacterial infections if left untreated. This can cause distress for affected individuals and parents.

Geographical Penetration

North America Accounted for Approximately 38.6% of the Market Share

North America is estimated to hold about 38.6% of the total market share throughout the forecast period, owing to the high prevalence of lice infestations among children, Product Innovation, advanced healthcare infrastructure, and rise in demand for chemical-free products, moreover, this region is having advanced technologies compared to another region which indeed helps this region to grow during the forecast period.

For instance, in August 2021 ParaPRO, a specialty pharmaceutical company, announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first new drug application for scabies approved by the FDA in over 30 years. The product is the first targeted topical treatment for scabies infestations in adult and pediatric patients aged four and older.

Competitive Landscape

The major global players in the market include: Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc., Johnson & Johnson Private Limited, Fleming Medical Ltd, RID Lice(Oystershell Consumer Health, Inc) Nisarg Pharma, ParaPRO Pharmaceuticals, ICB Pharma, Marico and among others.

COVID-19 Impact Analysis

COVID-19 pandemic had numerous impacts on the lice treatment market where the spread of head lice infestations among the tested groups of children was more. However, it remains unclear whether factors such as the separation of children into smaller groups or increased parental attention during lockdown contributed to the reduction in infestation rates compared to the period before the COVID-19 outbreak.

Thus, although COVID-19 has led to a shortage of essentials and created some hindrances, lice treatment has played an important role during COVID-19. Thus, the COVID-19 pandemic has impacted the growth of the studied market in the initial phase, however, currently; it is expected to have steady growth during the forecast period.

By Type

• Pediculosis Capitis
• Pediculosis Corporis
• Pediculosis Pubis

By Medication

• OTC Medication
  • Permethrin
  • Pyrethrin
  • Other Product Types

• Prescription Medication
  • Ivermectin
  • Spinosad
  • Malathion
  • By Distribution Channel

• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In October 2022, Alliance Pharmaceuticals collaborated with South Florida Family Health and Research Centers and posted a clinical trial on clinicaltrials.gov to check the safety and efficacy of Vamousse Spray 'n' Go, compared to a 1% Permethrin control shampoo, in the treatment of head lice.
• In September 2022, the American Academy of Pediatrics updated guidance on diagnosing and treating head lice. New medications for treatment were also mentioned and they provided an algorithm for the management of affected patients and further provided clarification on diagnosis and treatment.
• In October 2021, Lice Clinics of America announced that the company completed 750,000 successful head lice treatments using heated air, with a very high success rate.

Why Purchase the Report?

• To visualize the global lice treatment market segmentation based on type, medication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lice treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lice treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Medication
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Lice Infestation
    • 4.1.1.2. Rise in Product Approvals by Regulatory Authorities
    • 4.1.1.3. Increase in The Product Launches
    • 4.1.1.4. The Growing Population of Children Is Another Factor Supporting the Lice Treatment Market Share Growth.
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with Lice Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Rise in Research and Development
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Pediculosis Capitis *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pediculosis Corporis
• 7.4. Pediculosis Pubis

8. By Medication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 8.1.2. Market Attractiveness Index, By Medication
• 8.2. OTC Medications *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Prescription Medications

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospitals and Clinics *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Russia
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Alliance Pharmaceuticals*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Omega Pharma(Perrigo Company)
• 12.3. Prestige Brands Holdings Inc.
• 12.4. Johnson & Johnson Private Limited
• 12.5. Fleming Medical Ltd
• 12.6. RID Lice(Oystershell Consumer Health, Inc)
• 12.7. Nisarg Pharma
• 12.8. ParaPRO Pharmaceuticals
• 12.9. ICB Pharma
• 12.10. Marico

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us